The Latest

This Week in HIV Research: Delivering Care Through Uncertainty
Jan. 7, 2021: HIV status and COVID-19 disease severity; associations between tobacco smoking, cancer incidence, viral load, and CD4 count; immune recovery on integrase inhibitors; using smart pill bottles to boost adherence.

NIH Restructures HIV Clinical Trial Networks; AIDS Director Touts Milestones
“You could think of this as ‘who is in and who is out,’ but in reality [restructuring] is more like changing chairs,” said Carl Dieffenbach, Ph.D.

U.S. Waits on Approval of Long-Acting HIV Treatment Cabotegravir and Rilpivirine as European Union Gives the Green Light
The era of once-a-month HIV treatment has begun in the European Union—and it may soon commence in the U.S. as well. Long-acting pre-exposure prophylaxis (PrEP) is also on the horizon.

Lenacapavir Is the Most Important HIV Antiretroviral You Won’t Find in PubMed
This year, we got exciting new data about an HIV drug in development that may become an every-six-month, self-administered antiretroviral injection. But we learned about it via press release, rather than carefully presented research.

Long-Acting Injectable HIV Treatment Still Appears Safe and Effective—and Largely Accessible Despite COVID-19 Disruptions
Research newly presented at the IDWeek 2020 conference yields further promising data on injectable cabotegravir/rilpivirine, as well as encouraging info regarding COVID-19 disruptions in treatment delivery.

Researcher Behind "Brazil Patient," the Latest HIV Remission Case, Explains How It Happened
The international news story that broke at AIDS 2020, explained by the lead researcher.

This Champion of Community’s Role in Clinical Trials Reflects on 40 Years of Fighting Medical Mistrust And Research Neglect
Wakefield retires from the HIV Vaccine Trials Network after 20 years of service.

What Are the New HIV Treatment and Prevention Drugs Under Development in 2020?
Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.

Long-Acting Injectable HIV Meds Just as Good as Daily Pill for Newly Diagnosed and Those Already Undetectable
Questions still remain as to when FDA will approve, and how it will be implemented.

CROI 2020: What to Expect in HIV Science From This Year’s Conference
COVID-19 will impact both the program content and attendees this year, but there are still important HIV science presentations.